Use of Maytenus Ilicifolia in the Treatment of Dyspepsia

This study is not yet open for participant recruitment.
Verified July 2011 by Casa Espirita Terra de Ismael
Sponsor:
Collaborator:
University of Sao Paulo
Information provided by:
Casa Espirita Terra de Ismael
ClinicalTrials.gov Identifier:
NCT01408849
First received: July 29, 2011
Last updated: August 2, 2011
Last verified: July 2011
  Purpose

This study aims to evaluate the therapeutic effect of the infusion of Maytenus ilicifolia Mart. ex Reiss leaves, used for 8 weeks, on patients with dyspepsia. Primary endpoint is SODA score, secondary endpoint is endoscopic classification (Sydney).


Condition Intervention Phase
Dyspepsia
Drug: Maytenus ilicifolia leaves infusion
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of Maytenus Ilicifolia Mart. ex Reiss in the Treatment of Dyspepsia

Resource links provided by NLM:


Further study details as provided by Casa Espirita Terra de Ismael:

Primary Outcome Measures:
  • SODA score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The SODA score will be assessed before treatment and after 8 weeks of treatment


Secondary Outcome Measures:
  • Sydney classification [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The Sydney classification will be done before treatment and after 8 weeks of treatment


Estimated Enrollment: 20
Study Start Date: September 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Maytenus ilicifolia leaves infusion
    2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 18 years
  • being literate
  • diagnosis of dyspepsia
  • initial SODA score > or = 25

Exclusion Criteria:

  • pregnancy
  • lactation
  • allergy to Maytenus species
  • fail to use the drug for 3 uninterrupted weeks
  • new onset serious adverse events, attributable to the drug
  • patient's request
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01408849

Contacts
Contact: Fabio Carmona, MD, PhD 5516-3602-2478 carmona@fmrp.usp.br
Contact: Suzeidi B Castanheira, MD, PhD 5516-3621-8708 suzirp@hotmail.com

Locations
Brazil
Hospital das Clinicas FMRP-USP Not yet recruiting
Ribeirao Preto, SP, Brazil, 14049-900
Contact: Suzeido B Castanheira, MD, PhD     5516-3621-8708     suzirp@hotmail.com    
Principal Investigator: Suzeidi B Castanheira, MD, PhD            
Sponsors and Collaborators
Casa Espirita Terra de Ismael
University of Sao Paulo
Investigators
Study Director: Ana MS Pereira, PhD UNAERP
Study Chair: Jose S Santos, MD, PhD HCFMRP-USP
Principal Investigator: Fabio Carmona, MD, PhD HCFMRP-USP
Principal Investigator: Suzeidi B Castanheira, MD, PhD HCFMRP-USP
  More Information

No publications provided

Responsible Party: Fabio Carmona, HCFMRP-USP
ClinicalTrials.gov Identifier: NCT01408849     History of Changes
Other Study ID Numbers: Maytenus2011
Study First Received: July 29, 2011
Last Updated: August 2, 2011
Health Authority: Brazil: Conselho Nacional de Etica em Pesquisa (CONEP)

Keywords provided by Casa Espirita Terra de Ismael:
Endoscopy
Herbal medicine
Phytotherapy

Additional relevant MeSH terms:
Dyspepsia
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on June 17, 2013